AbbVie in Talks to Acquire Gilgamesh in $1 Billion Deal

AbbVie Inc., a leading pharmaceutical company, is in negotiations to acquire Gilgamesh Pharmaceuticals, a firm specializing in mental health treatments. The potential deal is valued at around $1 billion, reflecting the increasing interest in the mental health therapeutics industry. Gilgamesh Pharmaceuticals is known for developing innovative solutions to address various mental health conditions. The acquisition, if finalized, would allow AbbVie to expand its portfolio and strengthen its presence in the rapidly evolving mental health market. The discussions are ongoing, and the terms of the potential deal are still being finalized. Neither company has made any official statements regarding the matter, and the transaction's completion is subject to customary regulatory approvals and other closing conditions. The potential acquisition highlights the growing importance of mental health treatments in the pharmaceutical industry, as companies seek to address the rising demand for effective and accessible mental health solutions.